Form 4: Labcorp Executive's Stock Transactions

Labcorp's EVP, CIO & CTO, Akinbolade Oyegunwa, reported the acquisition of shares from RSU vesting and subsequent sale for tax obligations.

Summary

• Akinbolade Oyegunwa, EVP, CIO & CTO of Labcorp Holdings Inc., reported transactions involving company common stock.
• On November 1, 2025, 370 shares of common stock were acquired upon the vesting of Restricted Stock Units (RSUs).
• Following this acquisition, beneficial ownership of common stock was 3,834.253 shares.
• On November 3, 2025, 107 shares of common stock were disposed of at a price of $257.84 per share to satisfy tax withholding obligations.
• After these transactions, the direct beneficial ownership of common stock stands at 3,727.253 shares.
• The reporting person also holds 1,939 aggregate Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing details a routine executive compensation event involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. This is a standard practice and generally viewed as neutral to slightly positive, reflecting ongoing executive incentive alignment.

Positives

• The vesting of 370 Restricted Stock Units indicates the fulfillment of executive compensation incentives.
• Continued holding of 3,727.253 shares of common stock and 1,939 RSUs by a key executive demonstrates ongoing alignment with shareholder interests.

Negatives

• The disposition of 107 shares of common stock, while for tax purposes, represents a reduction in the executive's direct equity holding.

Future Outlook

Restricted Stock Units are scheduled to vest in three equal annual installments, beginning on November 1, 2025, indicating future equity compensation events.

Industry Context

This transaction is a routine executive compensation event, common across publicly traded companies where equity incentives like Restricted Stock Units are used to align management interests with shareholder value. The sale of shares to cover tax obligations upon vesting is a standard practice.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice across various industries, including healthcare and diagnostics, aligning executive incentives with long-term company performance.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a standard and expected procedure, consistent with practices observed in comparable companies and executive compensation plans.

Stakeholder Impact

• Shareholders: Minor impact, as these are routine executive compensation transactions and do not signal a change in company fundamentals.
• Employees: No direct impact beyond the reporting executive.
• Management: The executive's compensation structure includes equity incentives, aligning their interests with long-term company performance.

Next Steps

• Future vesting of remaining Restricted Stock Units in two more equal annual installments following November 1, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and a subsequent sale for tax purposes. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as the filing does not alter the fundamental investment thesis for Labcorp Holdings Inc.

Keywords

Labcorp, LH, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, RSU Vesting, Stock Sale